Literature DB >> 2131925

Short and long-term effect of two different dosages of ranitidine in the therapy of reflux oesophagitis.

F Pace1, O Sangaletti, G Bianchi Porro.   

Abstract

Many clinical trials on the effects of H2-antagonist drugs on reflux oesophagitis have shown unsatisfactory healing rates after conventional therapy, i.e. 4 to 12-week administration of 400 or 150mg bd of cimetidine or ranitidine, respectively. In order to verify if longer periods of treatment and/or higher dosage of drug can increase the healing rate, we performed a single-center double blind trial of 12 to 24 week duration on 75 patients with erosive/ulcerative reflux oesophagitis, comparing two ranitidine regimens, 150 vs 300mg bd. Patients who were healed after this period entered a 12 month maintenance treatment with half the dose previously received, i.e. 150 vs 300mg at bedtime. Our results show that, with both dosages, prolongation of acute treatment from 12 to 24 weeks allows complete additional healing of almost one fourth of patients. Furthermore, the data show that, both in the short and long-term treatment of reflux oesophagitis, conventional doses of ranitidine are as effective as double doses.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2131925

Source DB:  PubMed          Journal:  Ital J Gastroenterol        ISSN: 0392-0623


  5 in total

1.  Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis.

Authors:  Wei-Hong Wang; Jia-Qing Huang; Ge-Fan Zheng; Harry Hua-Xiang Xia; Wai-Man Wong; Shiu-Kum Lam; Benjamin Chun-Yu Wong
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

2.  Economic evaluation of long-term management strategies for erosive oesophagitis.

Authors:  R Goeree; B O'Brien; R Hunt; G Blackhouse; A Willan; J Watson
Journal:  Pharmacoeconomics       Date:  1999-12       Impact factor: 4.981

Review 3.  A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials.

Authors:  N Sharma; C Donnellan; C Preston; B Delaney; G Duckett; P Moayyedi
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

4.  Natural history of gastro-oesophageal reflux disease without oesophagitis.

Authors:  F Pace; F Santalucia; G Bianchi Porro
Journal:  Gut       Date:  1991-08       Impact factor: 23.059

Review 5.  Pharmacological management of gastro-oesophageal reflux disease.

Authors:  E C Klinkenberg-Knol; H P Festen; S G Meuwissen
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.